QUINCE THERAPEUTICS INC (QNCX) Stock Income Statement
NASDAQ:QNCX - Nasdaq - US22053A1079 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 43.80M | 40.16M | 28.72M | 51.19M | 90.32M | |||
| Research and Development | 27.20M | 18.59M | 9.45M | 25.18M | 60.80M | |||
| Selling, General, and Administrative Expenses | 13.23M | 17.58M | 17.70M | 26.01M | 29.52M | |||
| Operating Income | -43.80M | -40.16M | -28.72M | -51.19M | -90.32M | |||
| Interest Income/Expense | 2.45M | 2.93M | 3.48M | 1.07M | 620.00K | |||
| Other Income/Expense | -2.13M | -2.38M | -374.00K | -1.00M | -250.00K | |||
| Non Recurring Items | N/A | -17.13M | -5.97M | -830.00K | N/A | |||
| Income Before Taxes | -60.61M | -56.74M | -31.58M | -51.94M | -89.95M | |||
| Income Tax | 103.00K | 87.00K | -197.00K | -280.00K | N/A | |||
| Net Income | -60.71M | -56.83M | -31.39M | -51.66M | -89.95M | |||
| EBITDA | -43.62M | -39.97M | -28.40M | -50.99M | -89.98M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.40 | -1.31 | -0.84 | -1.54 | -3.03 | |||
| Non GAAP EPS | N/A | N/A | N/A | N/A | -3.03 | |||
| Statistics | ||||||||
All data in USD